[144] Edgewise Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Edgewise Therapeutics (EWTX) filed a Form 144 reporting a proposed sale of 100,000 shares of common stock to be executed through Morgan Stanley Smith Barney LLC on 08/26/2025 with an aggregate market value of $1,459,760.00. The filing shows 105,345,708 shares outstanding, indicating the proposed sale represents roughly 0.095% of outstanding shares. The shares were acquired on 08/26/2025 by exercise of options under a registered plan and paid in cash the same day. The filing also discloses a prior sale in the past three months: 1,907 shares sold on 08/12/2025 by Alan J Russell for $25,534.73. The filer certifies no undisclosed material adverse information.

Positive

• None.

Negative

• Insider sale reported: Proposed sale of 100,000 shares valued at $1,459,760, which may be viewed negatively by some investors despite its small relative size.
• Recent insider activity: A sale of 1,907 shares on 08/12/2025 for $25,534.73 was disclosed, indicating ongoing insider liquidity actions.

Insights

Securities Analyst

TL;DR: Insider sale of 100,000 shares (~0.10% of float) following option exercise; transaction appears routine rather than material.

The filing reports an option exercise and immediate proposed sale of 100,000 common shares through Morgan Stanley with aggregate value of $1.46M. Because the shares were acquired via exercise under a registered plan and sold through a broker, this appears to be a routine liquidity event rather than a company-specific signal. The size of the proposed sale relative to total outstanding shares (~0.095%) is small, reducing the likelihood of a material impact on valuation. Recent smaller sale of 1,907 shares by Alan J Russell is disclosed and immaterial in magnitude.

Corporate Governance Expert

TL;DR: Proper Rule 144 disclosures filed; no indication of undisclosed material information per signer representation.

The Form 144 includes required detail: acquisition method (option exercise), payment in cash, broker identity, and estimated market value and date of sale. The signer’s attestation that they are unaware of undisclosed material adverse information is standard and important for compliance. From a governance perspective, the filing shows adherence to public-reporting obligations; the transaction sizes reported are modest relative to total shares outstanding.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	1459760.00	105345708	08/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/26/2025	Exercise of options under a registered plan	Issuer			100000	08/26/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ALAN J RUSSELL 1715 38th Street Boulder CO 80301	Common	08/12/2025	1907	25534.73

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Edgewise Therapeutics' Form 144 filed for EWTX disclose?

It reports a proposed sale of 100,000 common shares via Morgan Stanley on 08/26/2025 valued at $1,459,760.00, acquired by option exercise and paid in cash.

How large is the proposed sale relative to EWTX's outstanding shares?

The filing lists 105,345,708 shares outstanding; the proposed 100,000 share sale is roughly 0.095% of outstanding shares.

Were the shares sold immediately after acquisition?

Yes. The acquisition date and the payment date are both listed as 08/26/2025, indicating the shares were acquired by option exercise and paid for in cash the same day.

Is there any recent insider sale disclosed in the filing?

Yes. Alan J Russell sold 1,907 shares on 08/12/2025 for gross proceeds of $25,534.73.

Does the filer state there is undisclosed material information?

The filer signed the notice representing they do not know any material adverse information about the issuer that has not been publicly disclosed.